pH-Dependent modification of lipophilicity of porphyrin-type photosensitizers

Photodynamic disinfection and its role in controlling infectious diseases

Photodynamic therapy is witnessing a revival of its origins as a response to the rise of multi-drug resistant infections and the shortage of new classes of antibiotics. Photodynamic disinfection (PDDI) of microorganisms is making progresses in preclinical models and in clinical cases, and the perception of its role in the clinical armamentarium for the management of infectious diseases is changing. We review the positioning of PDDI from the perspective of its ability to respond to clinical needs. Emphasis is placed on the pipeline of photosensitizers that proved effective to inactivate biofilms, showed efficacy in animal models of infectious diseases or reached clinical trials. Novel opportunities resulting from the COVID-19 pandemic are briefly discussed. The molecular features of promising photosensitizers are emphasized and contrasted with those of photosensitizers used in the treatment of solid tumors. The development of photosensitizers has been accompanied by the fabrication of a variety of affordable and customizable light sources. We critically discuss the combination between photosensitizer and light source properties that may leverage PDDI and expand its applications to wider markets. The success of PDDI in the management of infectious diseases will ultimately depend on the efficacy of photosensitizers, affordability of the light sources, simplicity of the procedures, and availability of fast and efficient treatments.

Influences of experimental parameters on the stability of a benzoporphyrin drug in water/ethanol mixtures: a statistical approach investigation

The benzoporphyrin derivative, named B3B, is a promising new drug for application in photodynamic therapy. In aqueous organic solvent mixtures, B3B, can be used in topical application for superficial diseases, like for skin cancer. In this paper, the self-aggregation phenomena of porphyrin molecules in aqueous media was investigated using a chemometric tool to evaluate the effects of experimental variables on the stability of the B3B monomer in water/ethanol mixtures. A 23 factorial design was employed which permitted determination of the magnitude of experimental parameters which influence aggregation of the drug at different pHs using the minimum number of experiments. At first, the pK a values of the B3B in water/ethanol mixtures were determined by spectrophotometric measurements, resulting in pK a1 = 3.3 and pK a2 = 5.7, corresponding to the imino nitrogens and carboxylic groups, respectively. The experimental variables (B3B concentration, time and water/ethanol composition) were evaluated in three protonation states of the drug, at pH 7.0, 4.1 and 2.6. The two levels (low and high) were set up at: time 5 (-) and 360 minutes (+); [B3B] 4.4 × 10-6(-) and 26.5 × 10-6 M (+); and water content in ethanol 40 (-) and 60% (+). The main parameter that determines the magnitude of the effects seems to be the charge component of B3B, which can be modulated by the pH. The results from the 23 fractional design indicated that the main variable inducing B3B aggregation is the water percentage in ethanol at each pH selected. The magnitude of this effect was pronounced at pH 4.1 where the carboxylic and nitrogen free base forms of B3B are maintained. The factors of time and [B3B], despite being small, are not insignificant. Finally, the effect of water content was investigated in a wide range of water percentage in these three pHs.

Biodistribution and photodynamic efficacy of a water-soluble, stable, halogenated bacteriochlorin against melanoma

The in vitro phototoxicity of a photostable, synthetic, water-soluble, halogenated bacteriochlorin, 5,10,15,20-tetrakis(2-chloro-5-sulfophenyl)bacteriochlorin (TCPBSO3H), toward mouse melanoma (S91) cells is ∼60-fold higher than that of the analogous porphyrin, and is associated with very weak toxicity in the dark; 90% of S91 cells were killed in response to a light dose of 0.26 J cm(-2) in the presence of [TCPBSO3H]=5 μM. In vivo toxicity toward DBA mice is very low, even at doses of 20 mg kg(-1). In vivo pharmacokinetics and biodistribution of TCPBSO3H were studied in DBA mice with S91 tumors; 24 h after intraperitoneal injection of 10 mg kg(-1), TCPBSO3H demonstrated preferential accumulation in S91 mouse melanoma, with tumor-to-normal tissue ratios of 3 and 5 for muscle and skin, respectively. Photodynamic therapy (PDT) performed under these conditions, with 90 mW cm(-2) diode laser irradiation at λ 750 nm for 20 min (total light dose of 108 J cm(-2)), resulted in tumor regression. Tumor recurrence was observed only approximately two months after treatment, confirming the efficacy of this PDT against melanoma.